655 related articles for article (PubMed ID: 23941826)
1. A semisynthetic taxane Yg-3-46a effectively evades P-glycoprotein and β-III tubulin mediated tumor drug resistance in vitro.
Cai P; Lu P; Sharom FJ; Fang WS
Cancer Lett; 2013 Dec; 341(2):214-23. PubMed ID: 23941826
[TBL] [Abstract][Full Text] [Related]
2. Modification of C-seco taxoids through ring tethering and substituent replacement leading to effective agents against tumor drug resistance mediated by βIII-Tubulin and P-glycoprotein (P-gp) overexpressions.
Tang Y; Rodríguez-Salarichs J; Zhao Y; Cai P; Estévez-Gallego J; Balaguer-Pérez F; Redondo Horcajo M; Lucena-Agell D; Barasoain I; Díaz JF; Fang WS
Eur J Med Chem; 2017 Sep; 137():488-503. PubMed ID: 28624703
[TBL] [Abstract][Full Text] [Related]
3. Lx2-32c, a novel taxane derivative, exerts anti-resistance activity by initiating intrinsic apoptosis pathway in vitro and inhibits the growth of resistant tumor in vivo.
Zhou Q; Li Y; Jin J; Lang L; Zhu Z; Fang W; Chen X
Biol Pharm Bull; 2012; 35(12):2170-9. PubMed ID: 23207769
[TBL] [Abstract][Full Text] [Related]
4. 5-(3,4,5-trimethoxybenzoyl)-4-methyl-2-(p-tolyl) imidazol (BZML) targets tubulin and DNA to induce anticancer activity and overcome multidrug resistance in colorectal cancer cells.
Bai Z; Liu X; Guan Q; Ding N; Wei Q; Tong B; Zhao M; Zhang W; Ma L
Chem Biol Interact; 2020 Jan; 315():108886. PubMed ID: 31682804
[TBL] [Abstract][Full Text] [Related]
5. Preclinical pharmacologic evaluation of MST-997, an orally active taxane with superior in vitro and in vivo efficacy in paclitaxel- and docetaxel-resistant tumor models.
Sampath D; Greenberger LM; Beyer C; Hari M; Liu H; Baxter M; Yang S; Rios C; Discafani C
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3459-69. PubMed ID: 16740771
[TBL] [Abstract][Full Text] [Related]
6. Taxanes with high potency inducing tubulin assembly overcome tumoural cell resistances.
Matesanz R; Trigili C; Rodríguez-Salarichs J; Zanardi I; Pera B; Nogales A; Fang WS; Jímenez-Barbero J; Canales A; Barasoain I; Ojima I; Díaz JF
Bioorg Med Chem; 2014 Sep; 22(18):5078-90. PubMed ID: 25047938
[TBL] [Abstract][Full Text] [Related]
7. Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone.
Roque DM; Bellone S; Buza N; Romani C; Cocco E; Bignotti E; Ravaggi A; Rutherford TJ; Schwartz PE; Pecorelli S; Santin AD
Am J Obstet Gynecol; 2013 Jul; 209(1):62.e1-9. PubMed ID: 23583215
[TBL] [Abstract][Full Text] [Related]
8. Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells.
Koo JS; Choi WC; Rhee YH; Lee HJ; Lee EO; Ahn KS; Bae HS; Ahn KS; Kang JM; Choi SU; Kim MO; Lu J; Kim SH
Life Sci; 2008 Nov; 83(21-22):700-8. PubMed ID: 18845169
[TBL] [Abstract][Full Text] [Related]
9. A novel taxane, difluorovinyl-ortataxel, effectively overcomes paclitaxel-resistance in breast cancer cells.
Rong D; Wang C; Zhang X; Wei Y; Zhang M; Liu D; Farhan H; Momen Ali SA; Liu Y; Taouil A; Guo W; Wang Y; Ojima I; Yang S; Wang H
Cancer Lett; 2020 Oct; 491():36-49. PubMed ID: 32730778
[TBL] [Abstract][Full Text] [Related]
10. Co-delivery of Se nanoparticles and pooled SiRNAs for overcoming drug resistance mediated by P-glycoprotein and class III β-tubulin in drug-resistant breast cancers.
Zheng W; Yin T; Chen Q; Qin X; Huang X; Zhao S; Xu T; Chen L; Liu J
Acta Biomater; 2016 Feb; 31():197-210. PubMed ID: 26612416
[TBL] [Abstract][Full Text] [Related]
11. Identification of a lathyrane-type diterpenoid EM-E-11-4 as a novel paclitaxel resistance reversing agent with multiple mechanisms of action.
Liu Q; Cai P; Guo S; Shi J; Sun H
Aging (Albany NY); 2020 Feb; 12(4):3713-3729. PubMed ID: 32108588
[TBL] [Abstract][Full Text] [Related]
12. MT-4 suppresses resistant ovarian cancer growth through targeting tubulin and HSP27.
Pai HC; Kumar S; Shen CC; Liou JP; Pan SL; Teng CM
PLoS One; 2015; 10(4):e0123819. PubMed ID: 25874627
[TBL] [Abstract][Full Text] [Related]
13. BZML, a novel colchicine binding site inhibitor, overcomes multidrug resistance in A549/Taxol cells by inhibiting P-gp function and inducing mitotic catastrophe.
Bai Z; Gao M; Zhang H; Guan Q; Xu J; Li Y; Qi H; Li Z; Zuo D; Zhang W; Wu Y
Cancer Lett; 2017 Aug; 402():81-92. PubMed ID: 28576750
[TBL] [Abstract][Full Text] [Related]
14. Antitumour activity of novel taxanes that act at the same time as cytotoxic agents and P-glycoprotein inhibitors.
Ferlini C; Distefano M; Pignatelli F; Lin S; Riva A; Bombardelli E; Mancuso S; Ojima I; Scambia G
Br J Cancer; 2000 Dec; 83(12):1762-8. PubMed ID: 11104578
[TBL] [Abstract][Full Text] [Related]
15. Novel taxane derivatives from Taxus wallichiana with high anticancer potency on tumor cells.
Wang Y; Wang J; Wang H; Ye W
Chem Biol Drug Des; 2016 Oct; 88(4):556-61. PubMed ID: 27153813
[TBL] [Abstract][Full Text] [Related]
16. Pseudolaric acid B, a novel microtubule-destabilizing agent that circumvents multidrug resistance phenotype and exhibits antitumor activity in vivo.
Wong VK; Chiu P; Chung SS; Chow LM; Zhao YZ; Yang BB; Ko BC
Clin Cancer Res; 2005 Aug; 11(16):6002-11. PubMed ID: 16115945
[TBL] [Abstract][Full Text] [Related]
17. P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5.
Park SJ; Wu CH; Choi MR; Najafi F; Emami A; Safa AR
Biochem Pharmacol; 2006 Jul; 72(3):293-307. PubMed ID: 16753135
[TBL] [Abstract][Full Text] [Related]
18. DTA0100, dual topoisomerase II and microtubule inhibitor, evades paclitaxel resistance in P-glycoprotein overexpressing cancer cells.
Podolski-Renić A; Banković J; Dinić J; Ríos-Luci C; Fernandes MX; Ortega N; Kovačević-Grujičić N; Martín VS; Padrón JM; Pešić M
Eur J Pharm Sci; 2017 Jul; 105():159-168. PubMed ID: 28502672
[TBL] [Abstract][Full Text] [Related]
19. Chamaecypanone C, a novel skeleton microtubule inhibitor, with anticancer activity by trigger caspase 8-Fas/FasL dependent apoptotic pathway in human cancer cells.
Hsieh CC; Kuo YH; Kuo CC; Chen LT; Cheung CH; Chao TY; Lin CH; Pan WY; Chang CY; Chien SC; Chen TW; Lung CC; Chang JY
Biochem Pharmacol; 2010 May; 79(9):1261-71. PubMed ID: 20034474
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and Cytotoxicity of 7,9-
Zhao Y; Wang TE; Mills A; Gago F; Fang WS
Molecules; 2019 Jun; 24(11):. PubMed ID: 31181726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
